FDA investigating deaths of heparin patients

Just when you thought the heparin scare was over. The FDA and Baxter Healthcare are investigating the deaths of two Delaware patients who died after taking the blood thinner. Both patients--along with a third that suffered an adverse reaction--were using Baxter-supplied heparin, the Wall Street Journal reports, but there's no clear evidence that the drug caused the deaths.

Baxter was quick to point out that the active ingredient in the drugs those patients used came from Pfizer, not from bulk ingredient suppliers in China, as was the contaminated heparin that caused so much uproar last year. Pfizer, for its part, said it hasn't received any other reports of adverse reactions to the ingredient. The company gets its raw material for heparin from North American sources and from China, a Pfizer spokesman said. "Baxter believes the lot used in Delaware used North American raw materials," the spokesman told the WSJ.

Baxter pointed out that unlike last year's cases, these patients didn't develop severe low blood pressure. Instead, they developed intracranial bleeding. Plus, the company hasn't observed a rapid increase in adverse events from heparin as it did last year.

The Delaware hospital where both patients died emphasized that it's not sure heparin caused the deaths. "We are not pointing fingers at Baxter," a Beebe Medical Center spokesman told the Journal. "We don't know what's going on, but heparin is the only commonality that we were able to see ourselves."

- read the WSJ story
- get more from in-Pharma Technologist

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.